Neurocrine Biosciences NBIX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's total current liabilities?
- Neurocrine Biosciences (NBIX) reported total current liabilities of $831.7M in Q1 2026.
- How has Neurocrine Biosciences's total current liabilities changed year-over-year?
- Neurocrine Biosciences's total current liabilities increased by 59.1% year-over-year, from $522.9M to $831.7M.
- What is the long-term trend for Neurocrine Biosciences's total current liabilities?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's total current liabilities has grown at a 31.9% compound annual growth rate (CAGR), from $186.5M to $743.4M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.